Perception and Prevalence of Fungal Infections in Berlin - Brandenburg

Web-based Structured Survey of Retrospective Data of Invasive Mycosis in Intensive Care Patients in Berlin - Brandenburg

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01393002

Acronym

IFI_ICU

Enrollment

Registered

2011-07-13

Start date

2011-07-31

Completion date

2013-07-31

Last updated

2013-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive Mycosis

Keywords

intensive care, candidemia, fungal infection

Brief summary

This is a structured web-based survey in selected hospitals with intensive care units in Berlin- Brandenburg that will focus on the analysis of current knowledge in ICUs in the field of invasive mycoses.

Detailed description

Intensive care patients with invasive mycosis require a special clinical expertise especially in light of a high lethality. Early identification of patients at risk to develop a fungal infection is of utmost importance to start effective antifungal therapy. The implementation of current knowledge into clinical practice to fight fungal infection is not clear.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Intensive care units of hospitals in the INABBRA alliance. * Patients with invasive mycosis.

Exclusion criteria

* Hospitals without intensive care unit.

Design outcomes

Primary

Measure	Time frame	Description
Perception and prevalence of fungal infections	4 months	Perception and prevalence of fungal infections in ICU patients differs from real prevalence and leads to insufficient attribution of importance to this special medical condition.

Secondary

Measure	Time frame	Description
Practice - Surrogate markers for diagnosis and therapy of fungal infection and retrospective analysis of cases of invasive mycosis in a peer-review setting.	6 months	Qualitative and quantitative estimation of surrogate markers for diagnosis and treatment of invasive mycosis Number of bloodcultures per year Rate of bloodcultures positive for fungi ICD-10 diagnosis ICU length of stay for patients with invasive mycosis and/or fungal infection Hospital mortality for patients with invasive mycosis and/or fungal infection Number of patients treated by antimycotics per year Mean duration of antifungal treatment Defined daily doses of antimycotics given by hospital pharmacy

Countries

Germany

Outcome results